Abstract
MicroRNAs are short noncoding 18-25 nucleotide long RNA which bind and inhibit mRNA. Currently, there are over 1000 known human microRNAs, and microRNAs control over 50% of mammalian protein coding genes. MicroRNAs can be overexpressed or repressed in different diseases and inhibition or replacement of microRNAs is a promising area of study for therapeutics. Here we review the current knowledge of microRNA therapy, and discuss ways in which they can be utilized. We also discuss different methods of delivery of miRNA, and current clinical trials of microRNA-based therapies for disease. Finally we discuss the current limitations in the field, and how these limitations are being overcome.
Keywords: Antagomir, clinical trial, delivery, microRNA, microRNA mimic, therapeutic.
Mini-Reviews in Medicinal Chemistry
Title:MicroRNA Therapeutics: the Next Magic Bullet?
Volume: 15 Issue: 6
Author(s): Bridget Simonson and Saumya Das
Affiliation:
Keywords: Antagomir, clinical trial, delivery, microRNA, microRNA mimic, therapeutic.
Abstract: MicroRNAs are short noncoding 18-25 nucleotide long RNA which bind and inhibit mRNA. Currently, there are over 1000 known human microRNAs, and microRNAs control over 50% of mammalian protein coding genes. MicroRNAs can be overexpressed or repressed in different diseases and inhibition or replacement of microRNAs is a promising area of study for therapeutics. Here we review the current knowledge of microRNA therapy, and discuss ways in which they can be utilized. We also discuss different methods of delivery of miRNA, and current clinical trials of microRNA-based therapies for disease. Finally we discuss the current limitations in the field, and how these limitations are being overcome.
Export Options
About this article
Cite this article as:
Simonson Bridget and Das Saumya, MicroRNA Therapeutics: the Next Magic Bullet?, Mini-Reviews in Medicinal Chemistry 2015; 15 (6) . https://dx.doi.org/10.2174/1389557515666150324123208
DOI https://dx.doi.org/10.2174/1389557515666150324123208 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment
Current Vascular Pharmacology Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism Erythropoietin and Oxidative Stress
Current Neurovascular Research Subject Index To Volume 2
Current Psychiatry Reviews Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry Contraception in Women with Medical Conditions
Current Women`s Health Reviews Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs: Clinical Implications
Current Pharmaceutical Design Prevention of Cardiac Hypertrophy with Omega 3-Fatty Acids: Potential Cell Signaling Targets.
Current Organic Chemistry Herb-drug Interactions Involving Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Inflammatory Arthritis and Heart Disease
Current Pharmaceutical Design An Update on the Role of the Quality of LDL in Cardiovascular Risk:The Contribution of the Universities of Palermo and Zurich
Recent Patents on Cardiovascular Drug Discovery Systemic Sclerosis-Related Pulmonary Hypertension: Unique Characteristics and Future Treatment Targets
Current Pharmaceutical Design The Properties of Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) and its Applications in Tissue Engineering
Current Stem Cell Research & Therapy Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making
Current Pharmaceutical Biotechnology Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Natural Products in Regression and Slowing of Progression of Atherosclerosis
Current Pharmaceutical Biotechnology New Lipid-lowering Agents Acting on LDL Receptors
Current Topics in Medicinal Chemistry Perceval Sutureless Valve – are Sutureless Valves Here?
Current Cardiology Reviews